1251 GMT - Investors are souring on European pharmaceutical and biotech stocks, UBS analysts say in a research note. "Overall, sentiment is relatively negative for European pharma and biotech sector, and many investors see the sector as a source of funding for AI trades," the analysts say. There is interest in biotech, which can generate outsized returns if the right call is made at the right time, they add. Among European midsized pharma and biotech companies, Argenx, Genmab, Ipsen and UCB attract high investor interest, according to UBS. The Stoxx Europe 600 Health Care index rises 0.8%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 30, 2026 08:52 ET (12:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.